Bluepha is a Beijing-based firm that develops biomaterials. The company is backed by Tencent and has been operating from Beijing. It has completed an extended Series B fundraising round. Bluepha raised 400 million yuan (about $58.3 million) in the extension. The round was led by Zhong Ping Capital. The financing is described as an extended Series B equity round, indicating an extension of a prior Series B. Bluepha, founded in 2016 by Dr. Zhang Haoqian and Dr. Li Teng, focuses on molecular and material innovation using synthetic biotechnology. Its core products include biodegradable polyhydroxyalkanoates (PHA) and other bio-based molecules; a 25,000-ton annual-output PHA “super factory” began construction on January 1, 2022 in Binhai County, Yancheng City, Jiangsu Province. The company claims extensive technical reserves and IP across the PHA value chain—strain R&D, biotransformation, separation and purification, and material modification. Bluepha reports product performance verified by multiple Fortune 500 customers and has signed strategic cooperation agreements in major countries and regions to expand PHA’s global market. It is developing and deploying an industrial 4.0 SynBio_OS R&D platform to capture and reuse process data and engineering experience. The firm plans to use new funds to build and operate at-scale PHA production facilities and to advance R&D and commercialization of new pipelines such as regenerative medical materials and engineered probiotics. Bluepha is a Chinese synthetic biology firm that develops products and technologies in synthetic biology. The company has secured $66 million in funding. The capital is intended to accelerate its product development. The raise was reported in a China Digest roundup that also noted Space Transportation's $46 million close. The article does not provide operating metrics or further commercial details. No investor names or financing instrument details were disclosed in the coverage.

Total raised

$293M

Funding rounds

3

Latest round

Series B

Latest activity

Feb 2023